Shopping Cart
- Remove All
- Your shopping cart is currently empty
QN523 represents a novel scaffold with drug-like properties, showing potent in vitro cytotoxicity in a panel of 12 cancer cell lines. QN523 shows significant in vivo efficacy in a pancreatic cancer xenograft model. Autophagy is a major mechanism of action.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $30 | In Stock | |
5 mg | $68 | In Stock | |
10 mg | $107 | In Stock | |
25 mg | $218 | In Stock | |
50 mg | $343 | In Stock | |
100 mg | $493 | In Stock | |
200 mg | $685 | In Stock | |
1 mL x 10 mM (in DMSO) | $65 | In Stock |
Description | QN523 represents a novel scaffold with drug-like properties, showing potent in vitro cytotoxicity in a panel of 12 cancer cell lines. QN523 shows significant in vivo efficacy in a pancreatic cancer xenograft model. Autophagy is a major mechanism of action. |
In vitro | QN523 showed significant cytotoxicity with IC50 values ranging from 0.1 to 5.7 μM across 12 cell lines. QN523 at 0.5 μM and gemcitabine at 0.1 μM arrested MIA PaCa-2 cells in the S-phase following 24 and 48 h treatment[1]. |
In vivo | In NOD/SCID mice of MIA PaCa-2 xenografts, QN523 at 10 mg/kg (intraperitoneal administration) shows no significant delay in tumor growth from day 1 to day 9. QN523 at 20 mg/kg from day 10 and continued until day 44 delayed growth of the MIA PaCa-2 xenograft starting from day 17. On day 44 80% inhibition of tumor growth was observed. No symptoms of gross toxicity such as weakness, weight loss or lethargy were observed in the QN523 treatment group[1]. |
Molecular Weight | 250.26 |
Formula | C14H10N4O |
Cas No. | 878581-60-3 |
Smiles | O=C(Nc1cccc2cccnc12)c1cnccn1 |
Storage | Shipping with blue ice. | ||||||||||||||||||||||||||||||
Solubility Information | DMSO: 16.2 mg/mL (64.7 mM) | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.